Literature DB >> 9703306

Use of heparin in the treatment of protein-losing enteropathy after fontan operation for complex congenital heart disease.

A M Kelly1, R H Feldt, D J Driscoll, G K Danielson.   

Abstract

Protein-losing enteropathy (PLE) is a serious complication of the Fontan operation and is associated with pronounced mortality. Medical management of PLE has been only partially successful. A recent report noted dramatic improvement in patients with PLE within 3 weeks of subcutaneous administration of heparin. We report a case of reversal of PLE with resolution of clinical symptoms and normalization of serum albumin, total protein, and fecal alpha1-antitrypsin values after several months of heparin treatment. Our findings substantiate those recently reported but suggest that reversal of PLE may necessitate more than a few weeks of heparin therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703306     DOI: 10.4065/73.8.777

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  10 in total

1.  Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation.

Authors:  S Chakrabarti; B R Keeton; A P Salmon; J J Vettukattil
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

2.  Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation.

Authors:  V Westphal; S Murch; S Kim; G Srikrishna; B Winchester; R Day; H H Freeze
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Clinical research priorities in adult congenital heart disease.

Authors:  Timothy Cotts; Paul Khairy; Alexander R Opotowsky; Anitha S John; Anne Marie Valente; Ali N Zaidi; Stephen C Cook; Jamil Aboulhosn; Jennifer Grando Ting; Michelle Gurvitz; Michael J Landzberg; Amy Verstappen; Joseph Kay; Michael Earing; Wayne Franklin; Brian Kogon; Craig S Broberg
Journal:  Int J Cardiol       Date:  2013-12-24       Impact factor: 4.164

Review 4.  Congenital heart disease: current indications for antithrombotic therapy in pediatric patients.

Authors:  M D Reller
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

5.  Plastic bronchitis in children with Fontan palliation: analogue to protein losing enteropathy?

Authors:  B Stiller; F Riedel; K Paul; F K H van Landeghem
Journal:  Pediatr Cardiol       Date:  2002 Jan-Feb       Impact factor: 1.655

6.  Protein-Losing Enteropathy and Gastropathy.

Authors:  Brian R. Landzberg; Mark B. Pochapin
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

7.  The Fontan pathway: What's down the road?

Authors:  Sachin Khambadkone
Journal:  Ann Pediatr Cardiol       Date:  2008-07

8.  Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Authors:  Lars Bode; Camilla Salvestrini; Pyong Woo Park; Jin-Ping Li; Jeffrey D Esko; Yu Yamaguchi; Simon Murch; Hudson H Freeze
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 9.  Comparative pathophysiology and management of protein-losing enteropathy.

Authors:  Melanie D Craven; Robert J Washabau
Journal:  J Vet Intern Med       Date:  2019-02-14       Impact factor: 3.333

10.  Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection?

Authors:  Dominik Lenz; Jörg Hambsch; Peter Schneider; Hans-Jürgen Häusler; Ursula Sauer; John Hess; Attila Tárnok
Journal:  Crit Care       Date:  2003-03-03       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.